{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:49:07Z","timestamp":1793875747706,"version":"4.7.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.bneo.2025.100116","type":"journal-article","created":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T12:06:39Z","timestamp":1746965199000},"page":"100116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["A comparative assessment of molecular-based prognostic models in CMML"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5377-9252","authenticated-orcid":false,"given":"Luis E.","family":"Aguirre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najla","family":"Al Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1754-1204","authenticated-orcid":false,"given":"Somedeb","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7238-9241","authenticated-orcid":false,"given":"Akriti G.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0504-8233","authenticated-orcid":false,"given":"David A.","family":"Sallman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9040-7415","authenticated-orcid":false,"given":"Andrew T.","family":"Kuykendall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison R.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6248-3317","authenticated-orcid":false,"given":"Kendra","family":"Sweet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7751-7310","authenticated-orcid":false,"given":"Jeffrey E.","family":"Lancet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4707-7916","authenticated-orcid":false,"given":"Eric","family":"Padron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1876-5269","authenticated-orcid":false,"given":"Rami S.","family":"Komrokji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.bneo.2025.100116_bib1","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/leu.2013.100","article-title":"An evolutionary perspective on chronic myelomonocytic leukemia","volume":"27","author":"Itzykson","year":"2013","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.bneo.2025.100116_bib2","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1182\/blood-2012-06-440347","article-title":"Clonal architecture of chronic myelomonocytic leukemias","volume":"121","author":"Itzykson","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bneo.2025.100116_bib3","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1200\/JCO.1988.6.9.1417","article-title":"Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases","volume":"6","author":"Fenaux","year":"1988","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.bneo.2025.100116_bib4","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0145-2126(97)00192-6","article-title":"Problems in the classification of CMML--dysplastic versus proliferative type","volume":"22","author":"Germing","year":"1998","journal-title":"Leuk Res"},{"issue":"10","key":"10.1016\/j.bneo.2025.100116_bib5","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/S0025-6196(12)61287-7","article-title":"Chronic myelomonocytic leukemia: natural history and prognostic determinants","volume":"64","author":"Tefferi","year":"1989","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"10.1016\/j.bneo.2025.100116_bib6","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","article-title":"Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia","volume":"128","author":"Elena","year":"2016","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bneo.2025.100116_bib7","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1038\/leu.2014.125","article-title":"ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients","volume":"28","author":"Patnaik","year":"2014","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.bneo.2025.100116_bib8","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","article-title":"Prognostic score including gene mutations in chronic myelomonocytic leukemia","volume":"31","author":"Itzykson","year":"2013","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.bneo.2025.100116_bib9","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular International Prognostic Scoring System for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid"},{"issue":"12","key":"10.1016\/j.bneo.2025.100116_bib10","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2014-10-607341","article-title":"An international consortium proposal of uniform response criteria for myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN) in adults","volume":"125","author":"Savona","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bneo.2025.100116_bib11","article-title":"Characterization of Indolent Chronic Myelomonocytic Leukemia Phenotypes and Dynamic Features of Disease Progression","volume":"Published online 29 March 2025","author":"Aguirre","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.bneo.2025.100116_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.751668","article-title":"Molecular pathogenesis of chronic myelomonocytic leukemia and potential molecular targets for treatment approaches","volume":"11","author":"Geissler","year":"2021","journal-title":"Front Oncol"},{"issue":"24","key":"10.1016\/j.bneo.2025.100116_bib13","doi-asserted-by":"crossref","first-page":"9228","DOI":"10.1073\/pnas.84.24.9228","article-title":"RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes","volume":"84","author":"Janssen","year":"1987","journal-title":"Proc Natl Acad Sci"},{"issue":"7","key":"10.1016\/j.bneo.2025.100116_bib14","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2011.58","article-title":"Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms","volume":"25","author":"Abdel-Wahab","year":"2011","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.bneo.2025.100116_bib15","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1182\/blood-2010-03-274704","article-title":"Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value","volume":"116","author":"Smith","year":"2010","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.bneo.2025.100116_bib16","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1182\/blood-2010-10-311019","article-title":"Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A","volume":"118","author":"Jankowska","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bneo.2025.100116_bib17","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/leu.2009.59","article-title":"Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS\/MPN and AML","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.bneo.2025.100116_bib18","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/ajh.23373","article-title":"Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance","volume":"88","author":"Patnaik","year":"2013","journal-title":"Am J Hematol"},{"issue":"24","key":"10.1016\/j.bneo.2025.100116_bib19","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1200\/JCO.2009.27.1361","article-title":"Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1","volume":"28","author":"Kohlmann","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bneo.2025.100116_bib20","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1016\/S2352-3026(20)30374-4","article-title":"Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study","volume":"8","author":"Pleyer","year":"2021","journal-title":"Lancet Haematol"},{"issue":"7","key":"10.1016\/j.bneo.2025.100116_bib21","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/ajh.24735","article-title":"Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents","volume":"92","author":"Alfonso","year":"2017","journal-title":"Am J Hematol"},{"issue":"19","key":"10.1016\/j.bneo.2025.100116_bib22","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1002\/cncr.30814","article-title":"Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: a large population-based study","volume":"123","author":"Zeidan","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.bneo.2025.100116_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106640","article-title":"Leukocytosis is associated with end organ damage and mortality in chronic myelomonocytic leukemia and can be mitigated by cytoreductive therapy","volume":"109","author":"Hunter","year":"2021","journal-title":"Leuk Res"},{"issue":"7","key":"10.1016\/j.bneo.2025.100116_bib24","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/ajh.25488","article-title":"Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients","volume":"94","author":"Coston","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bneo.2025.100116_bib25","doi-asserted-by":"crossref","first-page":"10767","DOI":"10.1038\/ncomms10767","article-title":"Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents","volume":"7","author":"Merlevede","year":"2016","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.bneo.2025.100116_bib26","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood.2021015173","article-title":"Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysis [published correction appears in Blood. 2023;141(26):3232-3233]","volume":"140","author":"Robin","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2025.100116_bib27","doi-asserted-by":"crossref","first-page":"95.e1","DOI":"10.1016\/j.bbmt.2020.10.007","article-title":"Long-term survival benefit after allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia","volume":"27","author":"Gagelmann","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"10.1016\/j.bneo.2025.100116_bib28","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1158\/1078-0432.CCR-09-2112","article-title":"RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant","volume":"16","author":"Ricci","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.bneo.2025.100116_bib29","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/leu.2009.48","article-title":"RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation","volume":"23","author":"Kuo","year":"2009","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.bneo.2025.100116_bib30","first-page":"145","article-title":"The clinical, molecular, and mechanistic basis of RUNX1 mutations identified in hematological malignancies","volume":"43","author":"Yokota","year":"2020","journal-title":"Mol Cells"},{"issue":"2","key":"10.1016\/j.bneo.2025.100116_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171608","article-title":"Prognostic significance of SETBP1 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia, and chronic neutrophilic leukemia: a meta-analysis","volume":"12","author":"Shou","year":"2017","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.bneo.2025.100116_bib32","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1200\/JCO.22.00437","article-title":"Decitabine versus hydroxyurea for advanced proliferative chronic myelomonocytic leukemia: results of a randomized phase III trial within the EMSCO network","volume":"41","author":"Itzykson","year":"2023","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.bneo.2025.100116_bib33","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1200\/JCO.22.01784","article-title":"Real-world validation of Molecular International Prognostic Scoring System for myelodysplastic syndromes","volume":"41","author":"Sauta","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.bneo.2025.100116_bib34","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/s41375-023-01910-3","article-title":"Assessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromes","volume":"37","author":"Aguirre","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.bneo.2025.100116_bib35","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1038\/s41467-021-23186-w","article-title":"RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis","volume":"12","author":"Carr","year":"2021","journal-title":"Nat Commun"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100116_bib36","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1182\/blood-2024-205451","article-title":"CMML is in the eye of the Be_Who_ LDER: interrogating the newly proposed entity of Oligomonocytic Chronic Myelomonocytic Leukemia (O-CMML): MDS or CMML?","volume":"144","author":"Komrokji","year":"2024","journal-title":"Blood"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025000512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025000512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T01:41:38Z","timestamp":1764121298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328025000512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2950328025000512"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100116","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comparative assessment of molecular-based prognostic models in CMML","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100116","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100116"}}